HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology1182 papers

Hypertension

Last edited: 2 h ago

Overview

Hypertension, defined as persistently elevated blood pressure (BP) ≥130/80 mmHg, is a chronic condition characterized by sustained elevation of systemic arterial pressure 1 15. It is a leading global risk factor for cardiovascular disease (CVD), stroke, chronic kidney disease, and premature mortality 1 15 4. Hypertension predominantly affects adults, with increasing prevalence in older populations and notable disparities observed across racial/ethnic groups 4 20. Effective management is crucial in day-to-day practice to mitigate these severe health outcomes and improve quality of life 1 15.

Pathophysiology

The pathophysiology of hypertension involves complex interactions at multiple levels, from molecular to systemic. Initially, genetic predispositions and environmental factors such as diet, physical activity, and stress contribute to endothelial dysfunction and vascular stiffness 2 26. This dysfunction leads to increased vascular resistance, primarily due to vasoconstriction and hypertrophy of vascular smooth muscle cells 2 26. Additionally, alterations in the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system activation play pivotal roles in sustaining hypertension 1 16. Chronic inflammation and oxidative stress further exacerbate these processes, promoting vascular remodeling and impaired sodium handling by the kidneys, which collectively maintain elevated blood pressure 2 26.

Epidemiology

Hypertension affects approximately 1.13 billion adults globally, with a prevalence ranging from 25% to 40% in different populations 1 15. The condition disproportionately impacts older adults, with incidence increasing significantly after age 60 1 15. Gender differences exist, with men often having higher rates of hypertension in younger adulthood, though these patterns may converge in older age groups 1 15. Geographic disparities are notable, with higher prevalence observed in developed regions and certain ethnic groups, such as African Americans in the United States 4 20. Trends over time show a concerning rise in hypertension rates, partly attributed to lifestyle changes and aging populations 1 15.

Clinical Presentation

Hypertension is often asymptomatic in its early stages, making routine screening essential 1. Typical presentations may include headaches, dizziness, and nosebleeds, though these symptoms are not specific 1. Red-flag features include severe headaches, visual disturbances, chest pain, and shortness of breath, which may indicate hypertensive emergencies requiring urgent intervention 9. Atypical presentations can also occur, particularly in younger individuals, where hypertension might be discovered incidentally during routine health checks 2.

Diagnosis

The diagnostic approach to hypertension involves repeated measurements to confirm sustained elevation of blood pressure 1. Key criteria include:

Blood Pressure Measurement: ≥130/80 mmHg on at least two separate occasions 1 15.

Ambulatory Blood Pressure Monitoring (ABPM): Recommended for patients with suspected white-coat hypertension or masked hypertension 24 28.

Home Blood Pressure Monitoring: Valuable for assessing true ambulatory BP levels 1 24.

Target Organ Damage Assessment: Includes echocardiography for left ventricular hypertrophy, renal ultrasound, and retinal examination 1 15.

Differential Diagnosis:

White Coat Hypertension: Elevated BP in clinical settings but normal ambulatory BP 24.

Masked Hypertension: Normal clinic BP but elevated ambulatory BP 24.

Secondary Hypertension: Consider in younger patients or those with abrupt onset; requires evaluation for underlying causes like renal disease, endocrine disorders, or medication side effects 16 30.

Management

Initial Management

Lifestyle Modifications:

Diet: DASH diet rich in fruits, vegetables, and low-fat dairy products 1 15.

Weight Management: Achieve and maintain a healthy weight 1 15.

Physical Activity: At least 150 minutes of moderate-intensity aerobic activity per week 1 15.

Limiting Sodium Intake: <2300 mg/day, ideally <1500 mg/day for some patients 1 15.

Alcohol Consumption: Moderate intake; limit to ≤2 drinks/day for men and ≤1 drink/day for women 1 15.

Stress Management: Techniques such as mindfulness, meditation, and cognitive behavioral therapy 1 38.

First-Line Pharmacotherapy:

Thiazide Diuretics: Initial choice for most patients; e.g., hydrochlorothiazide 12.5-25 mg daily 1 15.

Angiotensin-Converting Enzyme (ACE) Inhibitors: e.g., lisinopril 10-20 mg daily 1 15.

Angiotensin II Receptor Blockers (ARBs): e.g., losartan 50 mg daily 1 15.

Calcium Channel Blockers (CCBs): e.g., amlodipine 5-10 mg daily 1 15.

Beta-Blockers: e.g., metoprolol 25-50 mg bid 13.

Second-Line Management

Combination Therapy: If BP targets not met with monotherapy, add another agent from a different class 1 15.

Alternative Agents: Consider alpha-blockers, direct renin inhibitors, or mineralocorticoid receptor antagonists (e.g., spironolactone) based on patient-specific factors 1 16.

Refractory Hypertension

Specialist Referral: Consider referral to hypertension specialists for resistant hypertension 1 9.

Renal Denervation: For resistant hypertension, especially in patients with no secondary cause 30.

Multidrug Regimens: Potentially include third or fourth antihypertensive agents, including centrally acting agents or direct vasodilators 1 15.

Contraindications:

Thiazide Diuretics: Severe renal impairment, hyperkalemia, gout 1.

ACE Inhibitors: Renal artery stenosis, pregnancy 1.

ARBs: Same as ACE inhibitors, plus caution in patients with history of angioedema 1.

Complications

Acute Complications

Hypertensive Crisis: Severe elevations leading to organ damage; requires immediate management 9.

Cerebrovascular Events: Stroke, intracranial hemorrhage 1 15.

Chronic Complications

Cardiovascular Disease: Coronary artery disease, heart failure, aortic dissection 1 15.

Renal Damage: Chronic kidney disease, end-stage renal disease 1 15.

Vision Loss: Retinopathy, potentially leading to blindness 1 15.

Management Triggers: Regular monitoring of BP, organ function tests, and lifestyle adherence are crucial to prevent complications 1 15.

Prognosis & Follow-up

The prognosis of hypertension varies based on control and associated risk factors. Effective BP management significantly reduces the risk of CVD and other complications 1 15. Prognostic indicators include achieving target BP levels, absence of target organ damage, and adherence to treatment regimens 1 15. Recommended follow-up intervals typically include:

Initial Monitoring: Monthly for the first 3-6 months 1.

Subsequent Monitoring: Every 3-6 months, adjusting based on stability and response to therapy 1.

Special Populations

Pediatrics

Diagnosis: BP ≥95th percentile for age, sex, and height 2.

Management: Focus on lifestyle modifications; pharmacological treatment considered for severe cases 2.

Elderly

Considerations: Polypharmacy, frailty, and cognitive impairment; individualized treatment goals 10 15.

Treatment: Start with lower doses and monitor closely for side effects 10.

Specific Ethnic Groups

African Americans: Higher prevalence and poorer control; tailored lifestyle interventions and aggressive pharmacological management recommended 4.

Asian Populations: Lower thresholds for treatment initiation; consider lower BP targets 15 20.

Pregnancy

Gestational Hypertension: Monitor closely; treatment individualized based on severity and gestational age 15.

Preeclampsia: Requires close obstetric and medical management to prevent maternal and fetal complications 15.

Key Recommendations

Target BP Goals: Achieve <130/80 mmHg in most adults, with consideration for lower targets (e.g., <120/80 mmHg) in high-risk patients (Evidence: Strong) 1 15 20.

Lifestyle Interventions: Implement comprehensive lifestyle modifications including diet, exercise, and sodium reduction (Evidence: Strong) 1 15.

Initial Pharmacotherapy: Start with thiazide diuretics, ACE inhibitors, ARBs, or CCBs (Evidence: Strong) 1 15.

Combination Therapy: Add another antihypertensive agent if BP targets are not met (Evidence: Moderate) 1 15.

Regular Monitoring: Schedule follow-up visits every 3-6 months to assess BP control and adjust therapy as needed (Evidence: Moderate) 1.

Special Populations: Tailor treatment goals and approaches for elderly, pediatric, and specific ethnic groups (Evidence: Moderate) 2 10 4 15.

Addressing Disparities: Implement strategies to reduce racial/ethnic disparities in hypertension management (Evidence: Expert opinion) 4.

Polypharmacy Management: Evaluate and deprescribe unnecessary medications in older adults to minimize risks (Evidence: Moderate) 46.

Intensive BP Control: Consider more intensive BP targets (e.g., <120/80 mmHg) in high-risk patients (Evidence: Strong) 20.

Ambulatory BP Monitoring: Use ABPM for patients with suspected white-coat or masked hypertension (Evidence: Moderate) 24 28.

References

Showing 100 most recent of 1182 indexed papers.

1 McCormack T, Wickham A, McDonagh STJ, Wiles MD, Faconti L, Brooks R et al.. Measurement and management of adult blood pressure in the peri-operative period: updated guidelines from the Association of Anaesthetists and the British and Irish Hypertension Society. Anaesthesia 2026. link 2 Flynn JT, Kruger R, Brady TM, Chanchlani R, Dionne J, Iturzaeta A et al.. Practical approach to evaluate and manage hypertension in youth: an International Society of Hypertension position paper. Journal of hypertension 2026. link 3 Grootaert MOJ, Luttun A. Blood vessels under pressure. Science (New York, N.Y.) 2026. link 4 Reddy TK, Ancha B, Grant JK, Ferdinand KC. Bridging the Gap in Racial/Ethnic Disparities: Perspectives from the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline. Current hypertension reports 2026. link 5 Roy D, Naik N, Kumar D, Mantoo MR, Banerjee PS, Srivastava P et al.. Cardinal aspects of treatment to control hypertension in India-2022 (CATCH 22): A survey on arterial hypertension management in young Indian adults: A report from cardiology society of India. Indian heart journal 2026. link 6 Ribeiro H, Matos Vilela E, Martos Gonçalves F, Gavina C, de Pinho R. A consensus statement from the Portuguese Society of Hypertension and the Portuguese Society of Cardiology for bridging the 2023-2025 hypertension Guidelines in clinical practice. Blood pressure 2026. link 7 Zhang R, Zhang D, Wang M, Tuerhong R, Hong J, Li N et al.. Nonlinear relationship between erythrocyte distribution width and albumin ratio and prevalence of gout in adult hypertensive patients. Clinical rheumatology 2026. link 8 He Y, Chen L, Jia J, Liu Y, Chen Y, Zhang X et al.. Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 9 Anyfanti P, Antza C, Karlafti E, Chovarda E, Triantafyllou K, Styliadis G et al.. Deviations in the diagnostic and management approach of hypertensive urgencies and emergencies in routine clinical practice as compared to the guidelines: a survey of physicians in tertiary hospitals. Journal of human hypertension 2026. link 10 Iwashima Y, Akasaki Y, Ito N, Nozato Y, Takami Y, Okochi J et al.. Consensus Statement on Practical Guidance for Optimizing Antihypertensive Therapy in Older Adults Needing Nursing Care by the Japan Geriatrics Society and the Japanese Society of Hypertension: English Translation of the Japanese Article. Geriatrics & gerontology international 2026. link 11 Do Amaral Juniot OL, Carniel TA, Corralo VDS, Ferretti FK, De Sá CA. Association Between Polypharmacy and Socioeconomic and Demographic Factors in Adults Aged 50 Years and Older by Brazilian Macroregions. Pharmacoepidemiology and drug safety 2026. link 12 Gilmore S, Wallace E, Doherty AS. Investigating Potential Prescribing Cascades Resulting in Prochlorperazine Prescription: An Exploratory Analysis of Antihypertensives and NSAIDs. Drugs & aging 2026. link 13 Du Y, Zhang M, Luo Z, Liang Z, Liang W, Chen Z et al.. Metoprolol adverse events and literature analyses: case/non-case analyses using the FDA Adverse Event Reporting System (FAERS). Expert opinion on drug safety 2026. link 14 Shan M, Guo Q, Li R, Li N, Fu Y, Qi H et al.. Real-world safety of aliskiren in primary hypertension: A cross-database study. PloS one 2026. link 15 Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al.. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979) 2025. link 16 Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ et al.. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism 2025. link 17 Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al.. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2025. link 18 Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G et al.. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2025. link 19 Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al.. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology 2025. link 20 Brandão AA, Rodrigues CIS, Bortolotto LA, Luna LC, Barros BM, Neves MFT et al.. Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation. Arquivos brasileiros de cardiologia 2025. link 21 Eadon MT, Hein DW, Andersen MA, Chapman AB, Cooper-DeHoff RM, Desta Z et al.. Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clinical pharmacology and therapeutics 2025. link 22 Lauder L, Weber T, Böhm M, Brouwers S, Bruno RM, Gerdts E et al.. European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice. Nature reviews. Cardiology 2025. link 23 Liu H, Zuo X, Zhou Z, Ma Y, Wang B, Shi X. Antihypertensive Medication Adherence and Related Factors among Elderly Hypertensive Patients in China: A Meta-analysis. Indian journal of public health 2025. link 24 Parati G, Pengo MF, Avolio A, Azizi M, Bothe TL, Burnier M et al.. Nocturnal blood pressure: pathophysiology, measurement and clinical implications. Position paper of the European Society of Hypertension. Journal of hypertension 2025. link 25 Lv H, Li M, Liu H, Zhong Y, Wen H, Wang X. Acupuncture as Adjuvant Therapy for Hypertension in the Elderly: A Network Meta-Analysis. Journal of manipulative and physiological therapeutics 2025. link 26 Li W, Pu L, Meng Y, Wang X, Dong L, Yang Y et al.. Adverse childhood experiences contribute to blood pressure changes in adulthood: a meta-analysis of over 750 000 adults. Journal of global health 2025. link 27 Sabio R, Valdez P, Casariego Vales E, Cámera L, Puello Galarcio HL, Camafort M. Executive summary of the 2025 consensus on the diagnosis and treatment of hypertension of the International Forum on Internal Medicine. Revista clinica espanola 2025. link 28 Wanthong S, Chattranukulchai P, Chotruangnapa C, Kotruchin P, Roubsanthisuk W, Vathesatogkit P et al.. 2025 Thai Hypertension Society Guidance for Ambulatory Blood Pressure Monitoring in Adults. Journal of clinical hypertension (Greenwich, Conn.) 2025. link 29 Rodrigues CIS, Ferreira-Filho SR, Moura AFS, Poli-de-Figueiredo CE, Silva DRD, Polacchini FSG et al.. I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology. Jornal brasileiro de nefrologia 2025. link 30 Feriozzi S, Battaglia Y, Cirami CL, Gangemi C, La Manna G, Gesualdo L et al.. The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology. Journal of nephrology 2025. link 31 Faconti L, Tantirige N, Poulter NR, George J, Kapil V, Gupta A et al.. Call to action: British and Irish hypertension society position statement on blood pressure treatment thresholds and targets. Journal of human hypertension 2025. link 32 Asim R, Muhammad TS, Ahmed S, Khurram L, Azeem B, Doggar ME et al.. Dual-Targeted Therapy in Cardiometabolic Risk: A Meta-Analysis of Telmisartan-Based Combinations for Hypertension and Dyslipidemia. Clinical cardiology 2025. link 33 Tabarin A, Espiard S, Deutschbein T, Amar L, Vezzossi D, Di Dalmazi G et al.. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial. The lancet. Diabetes & endocrinology 2025. link00062-2) 34 Rosenberg K. Bedtime dosing of blood pressure medication has potential advantages. The American journal of nursing 2025. link 35 Rosenberg K. Nonstandard arm position could lead to overestimation of hypertension. The American journal of nursing 2025. link 36 Favaretto ALF, Duncan BB, Schmidt MI, Bittencourt MS, Barreto SM, Santos ABS et al.. Difference in the prevalence of hypertension when measured according to the American Heart Association and the European Society of Cardiology hypertension cut-offs in the ELSA-Brasil cohort. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 2025. link 37 McGarvey C, Scarlett S, Briggs R, McCrory C, McEvoy JW, Kenny RA et al.. Adherence to the European Society of Cardiology hypertension guidelines over 12 years of follow-up in the Irish population. Open heart 2025. link 38 Zhang L, Liu M. The Overlooked Driver of Hypertension: Mental Stress at the Crossroad of Cardiology and Psychiatry. Current atherosclerosis reports 2025. link 39 Asmar I, Almahmoud O, Jaghama M. Prevalence, awareness, and risk factors affecting hypertension according to 2017 American College of Cardiology and American Heart Association guidelines: a cross-sectional study from a developing country. Journal of hypertension 2025. link 40 Tocci G, Nardoianni G, Pala B, Citoni B, Virdis A, Muiesan ML et al.. Reclassification of patients with normal blood pressure levels after 2024 European society of cardiology guidelines on hypertension. Journal of hypertension 2025. link 41 McCarthy CP, Bruno RM, Rahimi K, Touyz RM, McEvoy JW. What Is New and Different in the 2024 European Society of Cardiology Guidelines for the Management of Elevated Blood Pressure and Hypertension?. Hypertension (Dallas, Tex. : 1979) 2025. link 42 Farag N, Bendary A, Elserafy AS, Abdellah AT, Zarif B, Elnady KY et al.. Blood Pressure Variability (BPV): What Clinicians Need to Know a 2025 Expert Consensus Report Endorsed by the Egyptian Society of Cardiology. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2025. link 43 Ihle-Hansen H, Walle-Hansen MM, Hagberg G, Berge T, Ihle-Hansen H, Rønningen PS et al.. Applying the 2024 European Society of Cardiology Guidelines for the management of elevated blood pressure and hypertension to a Norwegian general population cohort from age 40: data from the Akershus Cardiac Examination 1950 study. Heart (British Cardiac Society) 2025. link 44 Theofilis P, Nakas N, Lamprou T, Touchantzidou K, Vordoni A, Thimis V et al.. Hypertensive urgencies and emergencies in the cardiology emergency department: epidemiology, patient profile, and management. Journal of human hypertension 2025. link 45 Schultz MG, Currie KD, Hedman K, Maiorana A, Climie RE, Littlechild D et al.. Exercise and Sports Science Australia (ESSA) - Consensus Statement: Exercise blood pressure for the identification of uncontrolled hypertension: recommendations to support best-practice blood pressure management. Journal of science and medicine in sport 2025. link 46 Vucenovic A, Kraut RY, Manca DP, Sadowski CA. Barriers and Facilitators to Pharmacist-Led Deprescribing of Antihypertensives in Long-Term Care: A Survey-Based Study. Basic & clinical pharmacology & toxicology 2025. link 47 Xu S, Gong P, Huang P, Liu L, Liu X, Liu T et al.. A study of medication safety in rural older people in Luzhou City. Frontiers in public health 2025. link 48 Yazie TS, Mengistu WE, Yimer YS, Dagnew SB, Dagnew FN, Moges TA et al.. Clinical factors associated with multimorbidity, polypharmacy and medication regimen complexity among adults with hypertension: a multicentre cross-sectional study. BMJ open 2025. link 49 McCarthy C, Moriarty F, Doherty AS, Feighery M, Boland F, Fahey T et al.. Prevalence and predictors of sub-optimal laboratory monitoring of selected higher risk medicines in Irish general practice: a 5-year retrospective cohort study of community-dwelling older adults. BMJ open 2025. link 50 Hiremath G, Sherkhane R, Hiremath S. Evaluation of polypharmacy and appropriateness of prescription in geriatric patients using Beer's criteria at tertiary care hospital: a record based retrospective study. Journal of basic and clinical physiology and pharmacology 2025. link 51 Karkar Y, Anis T, Elkordy AA, Faheem A. Flexipill: A novel 3D printed flexible dose combination for hypertension with a floating element. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2025. link 52 Jamshidian MS, Scherzer R, Estrella MM, Kravitz RL, Boxer RS, Tancredi DJ et al.. Individualized Net Benefit of Intensive Blood Pressure Lowering Among Community-Dwelling Older Adults in SPRINT. Journal of the American Geriatrics Society 2025. link 53 Li CH, Hsueh SJ, Tsai LK, Chang WH, Cheng SY, Cheng HM et al.. Blood pressure targets, medication considerations and special concerns in elderly hypertension III: Focus on stroke and neurodegenerative disorders. Journal of the Formosan Medical Association = Taiwan yi zhi 2025. link 54 Silva IM, Moreira PM, Santos AM, Castro PR, Aguiar EC, Oliveira MG. Desprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial. International journal of clinical pharmacy 2025. link 55 Jeong JC, Kim U, Baek JH, Park JI. Malignant hypertension-induced multiorgan failure and acute limb ischemia in a young adult: A case report. Medicine 2025. link 56 Lin G, Chen R, Wen C, Li Z, Yan X, Li L. Analyzing real-world adverse events of spironolactone with the FAERS database. PloS one 2025. link 57 Sridharan K, Sivaramakrishnan G. A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA Adverse Event Reporting System. Expert opinion on drug safety 2025. link 58 Ju G, Chen L, Wang R, Zhang L, Liu Z, Chen S. A disproportionality analysis of nifedipine in the overall population and in pregnant women using the FDA Adverse Event Reporting System (FAERS) database. Medicine 2025. link 59 Zhu H, Pan L, Lui H, Zhang J. Drug-Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System. Journal of clinical hypertension (Greenwich, Conn.) 2025. link 60 Kulkarni S, Faconti L, Partridge S, Delles C, Glover M, Lewis P et al.. Investigation and management of young-onset hypertension: British and Irish hypertension society position statement. Journal of human hypertension 2024. link 61 Jabbarzadeh Ganjeh B, Zeraattalab-Motlagh S, Jayedi A, Daneshvar M, Gohari Z, Norouziasl R et al.. Effects of aerobic exercise on blood pressure in patients with hypertension: a systematic review and dose-response meta-analysis of randomized trials. Hypertension research : official journal of the Japanese Society of Hypertension 2024. link 62 Yap HJ, Lim JJJ, Tan SD, Ang CS. Effectiveness of digital health interventions on adherence and control of hypertension: a systematic review and meta-analysis. Journal of hypertension 2024. link 63 Grönroos R, Eggertsen R, Bernhardsson S, Praetorius Björk M. Effects of beetroot juice on blood pressure in hypertension according to European Society of Hypertension Guidelines: A systematic review and meta-analysis. Nutrition, metabolism, and cardiovascular diseases : NMCD 2024. link 64 Sarafidis P, Schmieder R, Burnier M, Persu A, Januszewicz A, Halimi JM et al.. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024. link 65 Schjerven FE, Lindseth F, Steinsland I. Prognostic risk models for incident hypertension: A PRISMA systematic review and meta-analysis. PloS one 2024. link 66 Kokenge MC, Ruppar TM. Factors Influencing Antihypertensive Medication Adherence Among Historically Underrepresented Adults: A Meta-analysis. The Journal of cardiovascular nursing 2024. link 67 Chandrasekharam VVS, Babu R, Shah M. How effective is nephrectomy in curing hypertension in children with unilateral poorly functioning kidney? A systematic review. Pediatric surgery international 2024. link 68 Li Z, Xu S, Chen L, Jiang D. Effect of aspirin on blood pressure in hypertensive patients: a systematic review and meta-analysis. BMC cardiovascular disorders 2024. link 69 Wander GS, Panda JK, Pal J, Mathur G, Sahay R, Tiwaskar M et al.. Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians. The Journal of the Association of Physicians of India 2024. link 70 Bu Y, Zhang X, Song S, Su H, Yu Z, Guo Y. Association of greenspace with hypertension in adult: a systematic review and meta-analysis of epidemiological studies. International journal of environmental health research 2024. link 71 Silvinato A, Floriano I, Bernardo WM. Renal denervation by radiofrequency in patients with hypertension: systematic review and meta-analysis. Revista da Associacao Medica Brasileira (1992) 2024. link 72 Kato H, Kitamoto T, Kimura S, Sunouchi T, Hoshino Y, Hidaka N et al.. Cardiovascular Outcomes of KCNJ5 Mutated Aldosterone-Producing Adenoma: A Systematic Review. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2024. link 73 Zweiker D, Koppelstätter C, Hohenstein K, Lang I, Perl S, Bugger H et al.. Renal sympathetic denervation 2024 in Austria: recommendations from the Austrian Society of Hypertension : Endorsed by the Austrian Society of Nephrology and the Working Group of Interventional Cardiology of the Austrian Society of Cardiology. Wiener klinische Wochenschrift 2024. link 74 Qian J, Zhang M, Chen Z. A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients. Advances in therapy 2024. link 75 Hamza M, Kalsoom S, Riaz A. Comment on "renal denervation for hypertension". Current problems in cardiology 2024. link 76 Salman IM. Advancing cardiovascular neuromodulation: Aortic baroreceptor afferents act as targets for blood pressure control in hypertension. Science (New York, N.Y.) 2024. link 77 Ladele M. Delivering inclusive hypertensive care in the prison service. British journal of nursing (Mark Allen Publishing) 2024. link 78 Aung K, Htay T. In hypertension, with or without orthostatic hypotension, more- vs. less-intensive BP therapy improves clinical outcomes. Annals of internal medicine 2024. link 79 Stabile E, Muiesan ML, Ribichini FL, Sangiorgi G, Taddei S, Versaci F et al.. Italian Society of Interventional Cardiology (GISE) and Italian Society of Arterial Hypertension (SIIA) Position Paper on the role of renal denervation in the management of the difficult-to-treat hypertension. Minerva cardiology and angiology 2024. link 80 Mohamed Ali A, Khamis KM, Hauge SW, Hovstad T, Haaverstad R, Andemichael G et al.. The Zanzibar Heart Survey: A special report from a humanitarian cardiology program at the Mnazi Mmoja referral hospital, Zanzibar, United Republic of Tanzania by Haukeland University Hospital in Bergen, Norway. Current problems in cardiology 2024. link 81 Nain P, Stabellini N, Makram OM, Rast J, Yerraguntla S, Gopu G et al.. Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study. JNCI cancer spectrum 2024. link 82 Heaton J, Alshami A, Imburgio S, Mararenko A, Schoenfeld M, Sealove B et al.. Current Trends in Hypertension Identification and Management: Insights from the National Health and Nutrition Examination Survey (NHANES) Following the 2017 ACC/AHA High Blood Pressure Guidelines. Journal of the American Heart Association 2024. link 83 Goldie FC, Brady AJB. New National Institute for Health and Care Excellence guidance for hypertension: a review and comparison with the US and European guidelines. Heart (British Cardiac Society) 2024. link 84 Gulamhusein N, Turino Miranda K, Dumanski SM, González Bedat MC, Ulasi I, Conjeevaram A et al.. Sex- and Gender-Based Reporting in Antihypertensive Medication Literature Informing Hypertension Guidelines. Journal of the American Heart Association 2024. link 85 Goyal A, Jain H, Verma A, Jain J, Shamim U, Kanagala SG et al.. The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives. Current problems in cardiology 2024. link 86 Ferguson S, Hanlon BM, Ramly E, Messina ML, Ibrahim J, Rake P et al.. Rheumatology High Blood Pressure Protocol Reduces Disparities, But Delays Remain for External Primary Care. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2024. link 87 Song S, Cai X, Hu J, Zhu Q, Shen D, Ma H et al.. Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout. Frontiers in endocrinology 2024. link 88 Lu SY, Hsu HY, Hsieh YW, Lu CR, Huang HY, Chang SS. Prescribing cascades of antigout medications from thiazide diuretics in gout-naïve hypertensive adults receiving first-line pharmacological management. Scientific reports 2024. link 89 Che J, Tong J, Kuang X, Zheng C, He N, Liu Z. Hyperuricemia and gout enhanced the risk of long-term mortality in hypertension: insights from the National Health and Nutrition Examination Survey 2007-2018. Journal of hypertension 2024. link 90 Nacanabo WM, Seghda TAA, Dah DC, Sawadogo WLF, Sawadogo I, Dimzouré MS et al.. [Hypertensive emergencies at Bogodogo University Hospital, Ouagadougou (Burkina Faso)]. Medecine tropicale et sante internationale 2024. link 91 Koracevic G, Stojanovic M, Zdravkovic M, Lovic D, Simic D, Mladenovic K. Proposal of a Modified Classification of Hypertensive Crises: Urgency, Impending Emergency, and Emergency. Current vascular pharmacology 2024. link 92 Roth MA, Leyba K, Garg I, Madrid WH, Quazi MA, Sohail AH et al.. Mortality and in-patient outcomes in pheochromocytoma patients with hypertensive emergency in the United States: A propensity score matched analysis. Current problems in cardiology 2024. link 93 Evbayekha E, Okorare O, Ishola Y, Eugene O, Chike A, Abraham S et al.. Sociodemographic predictors of hypertensive crisis in the hospitalized population in the United States. Current problems in cardiology 2024. link 94 Paternoster G, Sangalli F, de Arroyabe BML, Bertini P, Brizzi G, D'Amora M et al.. Insights Into Perioperative Hypertension Management in Europe: Results From a Survey Endorsed by the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC). Journal of cardiothoracic and vascular anesthesia 2024. link 95 Eslami H, Halimi Milani F, Salehnia F, Kourehpaz N, Katebi K. Relationship between sublingual varices and hypertension: a systematic review and meta-analysis. BMC oral health 2024. link 96 Coulson HC, Brown M, Burke K, Griffith E, Shadiack V, Garner HR et al.. Common outpatient diagnoses and associated treatments logged by osteopathic medical students within a geriatric population. Journal of osteopathic medicine 2024. link 97 Steckelmacher J, Graham C, Maniero C, Gupta A. Managing hypertension in older people: current concepts. Drug and therapeutics bulletin 2024. link 98 Oliveira MG, Moreira PM, Amorim WW, Boockvar K. Deprescribing Hypertension Medication in Older Adults: Can It Lower Drug Burden Without Causing Harm?. Clinics in geriatric medicine 2024. link 99 Lin J, de Oliveira Costa J, Pearson SA, Buckley NA, Brieger D, Schutte AE et al.. Impact of coordinated care on adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia. Journal of hypertension 2024. link 100 Aguiñaga-Martínez N, Zavala-Rubio JD, Ramírez-Ruíz M, Hernández-Garza AJ, Segura-Chico M, Mata-Márquez MJ et al.. Prescription of non-steroidal anti-inflammatory and antirheumatic drugs in outpatient hypertensive patients. Gaceta medica de Mexico 2024. link

Original source

[1]
Measurement and management of adult blood pressure in the peri-operative period: updated guidelines from the Association of Anaesthetists and the British and Irish Hypertension Society. — McCormack T, Wickham A, McDonagh STJ, Wiles MD, Faconti L, Brooks R et al. Anaesthesia (2026)
[2]
Practical approach to evaluate and manage hypertension in youth: an International Society of Hypertension position paper. — Flynn JT, Kruger R, Brady TM, Chanchlani R, Dionne J, Iturzaeta A et al. Journal of hypertension (2026)
[3]
Blood vessels under pressure. — Grootaert MOJ, Luttun A Science (New York, N.Y.) (2026)
[4]
Bridging the Gap in Racial/Ethnic Disparities: Perspectives from the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline. — Reddy TK, Ancha B, Grant JK, Ferdinand KC Current hypertension reports (2026)
[5]
Cardinal aspects of treatment to control hypertension in India-2022 (CATCH 22): A survey on arterial hypertension management in young Indian adults: A report from cardiology society of India. — Roy D, Naik N, Kumar D, Mantoo MR, Banerjee PS, Srivastava P et al. Indian heart journal (2026)
[6]
A consensus statement from the Portuguese Society of Hypertension and the Portuguese Society of Cardiology for bridging the 2023-2025 hypertension Guidelines in clinical practice. — Ribeiro H, Matos Vilela E, Martos Gonçalves F, Gavina C, de Pinho R Blood pressure (2026)
[7]
Nonlinear relationship between erythrocyte distribution width and albumin ratio and prevalence of gout in adult hypertensive patients. — Zhang R, Zhang D, Wang M, Tuerhong R, Hong J, Li N et al. Clinical rheumatology (2026)
[8]
Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout. — He Y, Chen L, Jia J, Liu Y, Chen Y, Zhang X et al. Naunyn-Schmiedeberg's archives of pharmacology (2026)
[9]
Deviations in the diagnostic and management approach of hypertensive urgencies and emergencies in routine clinical practice as compared to the guidelines: a survey of physicians in tertiary hospitals. — Anyfanti P, Antza C, Karlafti E, Chovarda E, Triantafyllou K, Styliadis G et al. Journal of human hypertension (2026)
[10]
Consensus Statement on Practical Guidance for Optimizing Antihypertensive Therapy in Older Adults Needing Nursing Care by the Japan Geriatrics Society and the Japanese Society of Hypertension: English Translation of the Japanese Article. — Iwashima Y, Akasaki Y, Ito N, Nozato Y, Takami Y, Okochi J et al. Geriatrics & gerontology international (2026)
[11]
Association Between Polypharmacy and Socioeconomic and Demographic Factors in Adults Aged 50 Years and Older by Brazilian Macroregions. — Do Amaral Juniot OL, Carniel TA, Corralo VDS, Ferretti FK, De Sá CA Pharmacoepidemiology and drug safety (2026)
[12]
Investigating Potential Prescribing Cascades Resulting in Prochlorperazine Prescription: An Exploratory Analysis of Antihypertensives and NSAIDs. — Gilmore S, Wallace E, Doherty AS Drugs & aging (2026)
[13]
Metoprolol adverse events and literature analyses: case/non-case analyses using the FDA Adverse Event Reporting System (FAERS). — Du Y, Zhang M, Luo Z, Liang Z, Liang W, Chen Z et al. Expert opinion on drug safety (2026)
[14]
Real-world safety of aliskiren in primary hypertension: A cross-database study. — Shan M, Guo Q, Li R, Li N, Fu Y, Qi H et al. PloS one (2026)
[15]
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al. Hypertension (Dallas, Tex. : 1979) (2025)
[16]
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. — Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ et al. The Journal of clinical endocrinology and metabolism (2025)
[17]
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al. Circulation (2025)
[18]
Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. — Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G et al. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2025)
[19]
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al. Journal of the American College of Cardiology (2025)
[20]
Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation. — Brandão AA, Rodrigues CIS, Bortolotto LA, Luna LC, Barros BM, Neves MFT et al. Arquivos brasileiros de cardiologia (2025)
[21]
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. — Eadon MT, Hein DW, Andersen MA, Chapman AB, Cooper-DeHoff RM, Desta Z et al. Clinical pharmacology and therapeutics (2025)
[22]
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice. — Lauder L, Weber T, Böhm M, Brouwers S, Bruno RM, Gerdts E et al. Nature reviews. Cardiology (2025)
[23]
Antihypertensive Medication Adherence and Related Factors among Elderly Hypertensive Patients in China: A Meta-analysis. — Liu H, Zuo X, Zhou Z, Ma Y, Wang B, Shi X Indian journal of public health (2025)
[24]
Nocturnal blood pressure: pathophysiology, measurement and clinical implications. Position paper of the European Society of Hypertension. — Parati G, Pengo MF, Avolio A, Azizi M, Bothe TL, Burnier M et al. Journal of hypertension (2025)
[25]
Acupuncture as Adjuvant Therapy for Hypertension in the Elderly: A Network Meta-Analysis. — Lv H, Li M, Liu H, Zhong Y, Wen H, Wang X Journal of manipulative and physiological therapeutics (2025)
[26]
Adverse childhood experiences contribute to blood pressure changes in adulthood: a meta-analysis of over 750 000 adults. — Li W, Pu L, Meng Y, Wang X, Dong L, Yang Y et al. Journal of global health (2025)
[27]
Executive summary of the 2025 consensus on the diagnosis and treatment of hypertension of the International Forum on Internal Medicine. — Sabio R, Valdez P, Casariego Vales E, Cámera L, Puello Galarcio HL, Camafort M Revista clinica espanola (2025)
[28]
2025 Thai Hypertension Society Guidance for Ambulatory Blood Pressure Monitoring in Adults. — Wanthong S, Chattranukulchai P, Chotruangnapa C, Kotruchin P, Roubsanthisuk W, Vathesatogkit P et al. Journal of clinical hypertension (Greenwich, Conn.) (2025)
[29]
I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology. — Rodrigues CIS, Ferreira-Filho SR, Moura AFS, Poli-de-Figueiredo CE, Silva DRD, Polacchini FSG et al. Jornal brasileiro de nefrologia (2025)
[30]
The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology. — Feriozzi S, Battaglia Y, Cirami CL, Gangemi C, La Manna G, Gesualdo L et al. Journal of nephrology (2025)
[31]
Call to action: British and Irish hypertension society position statement on blood pressure treatment thresholds and targets. — Faconti L, Tantirige N, Poulter NR, George J, Kapil V, Gupta A et al. Journal of human hypertension (2025)
[32]
Dual-Targeted Therapy in Cardiometabolic Risk: A Meta-Analysis of Telmisartan-Based Combinations for Hypertension and Dyslipidemia. — Asim R, Muhammad TS, Ahmed S, Khurram L, Azeem B, Doggar ME et al. Clinical cardiology (2025)
[33]
Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial. — Tabarin A, Espiard S, Deutschbein T, Amar L, Vezzossi D, Di Dalmazi G et al. The lancet. Diabetes & endocrinology (2025)
[34]
Bedtime dosing of blood pressure medication has potential advantages. — Rosenberg K The American journal of nursing (2025)
[35]
Nonstandard arm position could lead to overestimation of hypertension. — Rosenberg K The American journal of nursing (2025)
[36]
Difference in the prevalence of hypertension when measured according to the American Heart Association and the European Society of Cardiology hypertension cut-offs in the ELSA-Brasil cohort. — Favaretto ALF, Duncan BB, Schmidt MI, Bittencourt MS, Barreto SM, Santos ABS et al. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas (2025)
[37]
Adherence to the European Society of Cardiology hypertension guidelines over 12 years of follow-up in the Irish population. — McGarvey C, Scarlett S, Briggs R, McCrory C, McEvoy JW, Kenny RA et al. Open heart (2025)
[38]
The Overlooked Driver of Hypertension: Mental Stress at the Crossroad of Cardiology and Psychiatry. — Zhang L, Liu M Current atherosclerosis reports (2025)
[39]
Prevalence, awareness, and risk factors affecting hypertension according to 2017 American College of Cardiology and American Heart Association guidelines: a cross-sectional study from a developing country. — Asmar I, Almahmoud O, Jaghama M Journal of hypertension (2025)
[40]
Reclassification of patients with normal blood pressure levels after 2024 European society of cardiology guidelines on hypertension. — Tocci G, Nardoianni G, Pala B, Citoni B, Virdis A, Muiesan ML et al. Journal of hypertension (2025)
[41]
What Is New and Different in the 2024 European Society of Cardiology Guidelines for the Management of Elevated Blood Pressure and Hypertension? — McCarthy CP, Bruno RM, Rahimi K, Touyz RM, McEvoy JW Hypertension (Dallas, Tex. : 1979) (2025)
[42]
Blood Pressure Variability (BPV): What Clinicians Need to Know a 2025 Expert Consensus Report Endorsed by the Egyptian Society of Cardiology. — Farag N, Bendary A, Elserafy AS, Abdellah AT, Zarif B, Elnady KY et al. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2025)
[43]
Applying the 2024 European Society of Cardiology Guidelines for the management of elevated blood pressure and hypertension to a Norwegian general population cohort from age 40: data from the Akershus Cardiac Examination 1950 study. — Ihle-Hansen H, Walle-Hansen MM, Hagberg G, Berge T, Ihle-Hansen H, Rønningen PS et al. Heart (British Cardiac Society) (2025)
[44]
Hypertensive urgencies and emergencies in the cardiology emergency department: epidemiology, patient profile, and management. — Theofilis P, Nakas N, Lamprou T, Touchantzidou K, Vordoni A, Thimis V et al. Journal of human hypertension (2025)
[45]
Exercise and Sports Science Australia (ESSA) - Consensus Statement: Exercise blood pressure for the identification of uncontrolled hypertension: recommendations to support best-practice blood pressure management. — Schultz MG, Currie KD, Hedman K, Maiorana A, Climie RE, Littlechild D et al. Journal of science and medicine in sport (2025)
[46]
Barriers and Facilitators to Pharmacist-Led Deprescribing of Antihypertensives in Long-Term Care: A Survey-Based Study. — Vucenovic A, Kraut RY, Manca DP, Sadowski CA Basic & clinical pharmacology & toxicology (2025)
[47]
A study of medication safety in rural older people in Luzhou City. — Xu S, Gong P, Huang P, Liu L, Liu X, Liu T et al. Frontiers in public health (2025)
[48]
Clinical factors associated with multimorbidity, polypharmacy and medication regimen complexity among adults with hypertension: a multicentre cross-sectional study. — Yazie TS, Mengistu WE, Yimer YS, Dagnew SB, Dagnew FN, Moges TA et al. BMJ open (2025)
[49]
Prevalence and predictors of sub-optimal laboratory monitoring of selected higher risk medicines in Irish general practice: a 5-year retrospective cohort study of community-dwelling older adults. — McCarthy C, Moriarty F, Doherty AS, Feighery M, Boland F, Fahey T et al. BMJ open (2025)
[50]
Evaluation of polypharmacy and appropriateness of prescription in geriatric patients using Beer's criteria at tertiary care hospital: a record based retrospective study. — Hiremath G, Sherkhane R, Hiremath S Journal of basic and clinical physiology and pharmacology (2025)
[51]
Flexipill: A novel 3D printed flexible dose combination for hypertension with a floating element. — Karkar Y, Anis T, Elkordy AA, Faheem A European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (2025)
[52]
Individualized Net Benefit of Intensive Blood Pressure Lowering Among Community-Dwelling Older Adults in SPRINT. — Jamshidian MS, Scherzer R, Estrella MM, Kravitz RL, Boxer RS, Tancredi DJ et al. Journal of the American Geriatrics Society (2025)
[53]
Blood pressure targets, medication considerations and special concerns in elderly hypertension III: Focus on stroke and neurodegenerative disorders. — Li CH, Hsueh SJ, Tsai LK, Chang WH, Cheng SY, Cheng HM et al. Journal of the Formosan Medical Association = Taiwan yi zhi (2025)
[54]
Desprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial. — Silva IM, Moreira PM, Santos AM, Castro PR, Aguiar EC, Oliveira MG International journal of clinical pharmacy (2025)
[55]
Malignant hypertension-induced multiorgan failure and acute limb ischemia in a young adult: A case report. — Jeong JC, Kim U, Baek JH, Park JI Medicine (2025)
[56]
Analyzing real-world adverse events of spironolactone with the FAERS database. — Lin G, Chen R, Wen C, Li Z, Yan X, Li L PloS one (2025)
[57]
A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA Adverse Event Reporting System. — Sridharan K, Sivaramakrishnan G Expert opinion on drug safety (2025)
[58]
A disproportionality analysis of nifedipine in the overall population and in pregnant women using the FDA Adverse Event Reporting System (FAERS) database. — Ju G, Chen L, Wang R, Zhang L, Liu Z, Chen S Medicine (2025)
[59]
Drug-Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System. — Zhu H, Pan L, Lui H, Zhang J Journal of clinical hypertension (Greenwich, Conn.) (2025)
[60]
Investigation and management of young-onset hypertension: British and Irish hypertension society position statement. — Kulkarni S, Faconti L, Partridge S, Delles C, Glover M, Lewis P et al. Journal of human hypertension (2024)
[61]
Effects of aerobic exercise on blood pressure in patients with hypertension: a systematic review and dose-response meta-analysis of randomized trials. — Jabbarzadeh Ganjeh B, Zeraattalab-Motlagh S, Jayedi A, Daneshvar M, Gohari Z, Norouziasl R et al. Hypertension research : official journal of the Japanese Society of Hypertension (2024)
[62]
Effectiveness of digital health interventions on adherence and control of hypertension: a systematic review and meta-analysis. — Yap HJ, Lim JJJ, Tan SD, Ang CS Journal of hypertension (2024)
[63]
Effects of beetroot juice on blood pressure in hypertension according to European Society of Hypertension Guidelines: A systematic review and meta-analysis. — Grönroos R, Eggertsen R, Bernhardsson S, Praetorius Björk M Nutrition, metabolism, and cardiovascular diseases : NMCD (2024)
[64]
A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. — Sarafidis P, Schmieder R, Burnier M, Persu A, Januszewicz A, Halimi JM et al. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
[65]
Prognostic risk models for incident hypertension: A PRISMA systematic review and meta-analysis. — Schjerven FE, Lindseth F, Steinsland I PloS one (2024)
[66]
Factors Influencing Antihypertensive Medication Adherence Among Historically Underrepresented Adults: A Meta-analysis. — Kokenge MC, Ruppar TM The Journal of cardiovascular nursing (2024)
[67]
How effective is nephrectomy in curing hypertension in children with unilateral poorly functioning kidney? A systematic review. — Chandrasekharam VVS, Babu R, Shah M Pediatric surgery international (2024)
[68]
Effect of aspirin on blood pressure in hypertensive patients: a systematic review and meta-analysis. — Li Z, Xu S, Chen L, Jiang D BMC cardiovascular disorders (2024)
[69]
Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians. — Wander GS, Panda JK, Pal J, Mathur G, Sahay R, Tiwaskar M et al. The Journal of the Association of Physicians of India (2024)
[70]
Association of greenspace with hypertension in adult: a systematic review and meta-analysis of epidemiological studies. — Bu Y, Zhang X, Song S, Su H, Yu Z, Guo Y International journal of environmental health research (2024)
[71]
Renal denervation by radiofrequency in patients with hypertension: systematic review and meta-analysis. — Silvinato A, Floriano I, Bernardo WM Revista da Associacao Medica Brasileira (1992) (2024)
[72]
Cardiovascular Outcomes of KCNJ5 Mutated Aldosterone-Producing Adenoma: A Systematic Review. — Kato H, Kitamoto T, Kimura S, Sunouchi T, Hoshino Y, Hidaka N et al. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2024)
[73]
Renal sympathetic denervation 2024 in Austria: recommendations from the Austrian Society of Hypertension : Endorsed by the Austrian Society of Nephrology and the Working Group of Interventional Cardiology of the Austrian Society of Cardiology. — Zweiker D, Koppelstätter C, Hohenstein K, Lang I, Perl S, Bugger H et al. Wiener klinische Wochenschrift (2024)
[74]
A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients. — Qian J, Zhang M, Chen Z Advances in therapy (2024)
[75]
Comment on "renal denervation for hypertension". — Hamza M, Kalsoom S, Riaz A Current problems in cardiology (2024)
[76]
Advancing cardiovascular neuromodulation: Aortic baroreceptor afferents act as targets for blood pressure control in hypertension. — Salman IM Science (New York, N.Y.) (2024)
[77]
Delivering inclusive hypertensive care in the prison service. — Ladele M British journal of nursing (Mark Allen Publishing) (2024)
[78]
In hypertension, with or without orthostatic hypotension, more- vs. less-intensive BP therapy improves clinical outcomes. — Aung K, Htay T Annals of internal medicine (2024)
[79]
Italian Society of Interventional Cardiology (GISE) and Italian Society of Arterial Hypertension (SIIA) Position Paper on the role of renal denervation in the management of the difficult-to-treat hypertension. — Stabile E, Muiesan ML, Ribichini FL, Sangiorgi G, Taddei S, Versaci F et al. Minerva cardiology and angiology (2024)
[80]
The Zanzibar Heart Survey: A special report from a humanitarian cardiology program at the Mnazi Mmoja referral hospital, Zanzibar, United Republic of Tanzania by Haukeland University Hospital in Bergen, Norway. — Mohamed Ali A, Khamis KM, Hauge SW, Hovstad T, Haaverstad R, Andemichael G et al. Current problems in cardiology (2024)
[81]
Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study. — Nain P, Stabellini N, Makram OM, Rast J, Yerraguntla S, Gopu G et al. JNCI cancer spectrum (2024)
[82]
Current Trends in Hypertension Identification and Management: Insights from the National Health and Nutrition Examination Survey (NHANES) Following the 2017 ACC/AHA High Blood Pressure Guidelines. — Heaton J, Alshami A, Imburgio S, Mararenko A, Schoenfeld M, Sealove B et al. Journal of the American Heart Association (2024)
[83]
New National Institute for Health and Care Excellence guidance for hypertension: a review and comparison with the US and European guidelines. — Goldie FC, Brady AJB Heart (British Cardiac Society) (2024)
[84]
Sex- and Gender-Based Reporting in Antihypertensive Medication Literature Informing Hypertension Guidelines. — Gulamhusein N, Turino Miranda K, Dumanski SM, González Bedat MC, Ulasi I, Conjeevaram A et al. Journal of the American Heart Association (2024)
[85]
The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives. — Goyal A, Jain H, Verma A, Jain J, Shamim U, Kanagala SG et al. Current problems in cardiology (2024)
[86]
Rheumatology High Blood Pressure Protocol Reduces Disparities, But Delays Remain for External Primary Care. — Ferguson S, Hanlon BM, Ramly E, Messina ML, Ibrahim J, Rake P et al. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2024)
[87]
Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout. — Song S, Cai X, Hu J, Zhu Q, Shen D, Ma H et al. Frontiers in endocrinology (2024)
[88]
Prescribing cascades of antigout medications from thiazide diuretics in gout-naïve hypertensive adults receiving first-line pharmacological management. — Lu SY, Hsu HY, Hsieh YW, Lu CR, Huang HY, Chang SS Scientific reports (2024)
[89]
Hyperuricemia and gout enhanced the risk of long-term mortality in hypertension: insights from the National Health and Nutrition Examination Survey 2007-2018. — Che J, Tong J, Kuang X, Zheng C, He N, Liu Z Journal of hypertension (2024)
[90]
[Hypertensive emergencies at Bogodogo University Hospital, Ouagadougou (Burkina Faso)]. — Nacanabo WM, Seghda TAA, Dah DC, Sawadogo WLF, Sawadogo I, Dimzouré MS et al. Medecine tropicale et sante internationale (2024)
[91]
Proposal of a Modified Classification of Hypertensive Crises: Urgency, Impending Emergency, and Emergency. — Koracevic G, Stojanovic M, Zdravkovic M, Lovic D, Simic D, Mladenovic K Current vascular pharmacology (2024)
[92]
Mortality and in-patient outcomes in pheochromocytoma patients with hypertensive emergency in the United States: A propensity score matched analysis. — Roth MA, Leyba K, Garg I, Madrid WH, Quazi MA, Sohail AH et al. Current problems in cardiology (2024)
[93]
Sociodemographic predictors of hypertensive crisis in the hospitalized population in the United States. — Evbayekha E, Okorare O, Ishola Y, Eugene O, Chike A, Abraham S et al. Current problems in cardiology (2024)
[94]
Insights Into Perioperative Hypertension Management in Europe: Results From a Survey Endorsed by the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC). — Paternoster G, Sangalli F, de Arroyabe BML, Bertini P, Brizzi G, D'Amora M et al. Journal of cardiothoracic and vascular anesthesia (2024)
[95]
Relationship between sublingual varices and hypertension: a systematic review and meta-analysis. — Eslami H, Halimi Milani F, Salehnia F, Kourehpaz N, Katebi K BMC oral health (2024)
[96]
Common outpatient diagnoses and associated treatments logged by osteopathic medical students within a geriatric population. — Coulson HC, Brown M, Burke K, Griffith E, Shadiack V, Garner HR et al. Journal of osteopathic medicine (2024)
[97]
Managing hypertension in older people: current concepts. — Steckelmacher J, Graham C, Maniero C, Gupta A Drug and therapeutics bulletin (2024)
[98]
Deprescribing Hypertension Medication in Older Adults: Can It Lower Drug Burden Without Causing Harm? — Oliveira MG, Moreira PM, Amorim WW, Boockvar K Clinics in geriatric medicine (2024)
[99]
Impact of coordinated care on adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia. — Lin J, de Oliveira Costa J, Pearson SA, Buckley NA, Brieger D, Schutte AE et al. Journal of hypertension (2024)
[100]
Prescription of non-steroidal anti-inflammatory and antirheumatic drugs in outpatient hypertensive patients. — Aguiñaga-Martínez N, Zavala-Rubio JD, Ramírez-Ruíz M, Hernández-Garza AJ, Segura-Chico M, Mata-Márquez MJ et al. Gaceta medica de Mexico (2024)